SCHEMBL5208474

SCHEMBL5208474

Cc1ccc(S(=O)(=O)NC(=O)[C@H]2CC[C@H](c3nc(-c4cccc(C(F)(F)F)c4)c[nH]3)CC2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 1/20 0.44
FFAR1 O14842 1/20 0.41
CDK1 P06493 1/20 0.41
CCNB1 P14635 1/20 0.41
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CDK7 P50613 1/20 0.41
CCNH P51946 1/20 0.41
CCNA1 P78396 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
XBP1 P17861 1/20 0.40
ALOX12 P18054 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5202968 1.00 KCNH2 (0.44) KCNH2FFAR1CDK1CCNB1CCNA2
SCHEMBL5207878 0.92 KCNH2 (0.46) KCNH2MEN1LMNAKMT2AJAK2
SCHEMBL5202747 0.91 KCNH2 (0.44) KCNH2LMNATP53MAPTJAK2
SCHEMBL5207987 0.88 KCNH2 (0.46) KCNH2L3MBTL1MEN1KMT2AJAK2
SCHEMBL5203621 0.84 KCNH2 (0.44) KCNH2MAPTJAK2SLC5A1KDM1A
SCHEMBL5203388 0.84 USP2 (0.40) KCNH2L3MBTL1MEN1KMT2AUSP2
SCHEMBL5202992 0.80 KCNH2 (0.46) KCNH2MEN1POLBKMT2AJAK2
SCHEMBL5203000 0.80 KCNH2 (0.46) KCNH2MEN1POLBKMT2AJAK2
SCHEMBL5206565 0.79 KCNH2 (0.47) KCNH2MEN1POLBKMT2AJAK2
SCHEMBL14608992 0.79 KCNH2 (0.47) KCNH2MEN1POLBKMT2AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
EP-1306085-B1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor NEUROGEN CORP (US) 2007-02-14 EP disclosed
US-7034034-B2 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION (US) 2006-04-25 US disclosed
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NEUROGEN CORPORATION 2003-07-31 US disclosed
EP-1306085-A1 2-Cyclohexyl-4-phenyl-1H-imidazole derivatives as ligands for the neuropeptide Y5 receptor Neurogen Corporation (US) 2003-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144290-A1 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives NPY5R, NPY4R, NPY1R KCNH2 1937/4885FFAR1 526/4885CDK1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.